ExodusPoint Capital Management LP Sells 172,224 Shares of Accuray Incorporated (NASDAQ:ARAY)

ExodusPoint Capital Management LP lessened its stake in shares of Accuray Incorporated (NASDAQ:ARAY – Get Rating) by 43.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 222,860 shares of the medical equipment provider’s stock after selling 172,224 shares during the period. ExodusPoint Capital Management LP’s holdings in Accuray were worth $464,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Y Intercept Hong Kong Ltd bought a new position in shares of Accuray during the 2nd quarter worth approximately $25,000. Zebra Capital Management LLC bought a new position in Accuray in the 1st quarter valued at $37,000. SG Americas Securities LLC raised its position in Accuray by 103.6% in the 2nd quarter. SG Americas Securities LLC now owns 22,305 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 11,352 shares during the last quarter. Mackenzie Financial Corp increased its stake in shares of Accuray by 36.9% in the 2nd quarter. Mackenzie Financial Corp now owns 26,627 shares of the medical equipment provider’s stock valued at $52,000 after buying an additional 7,171 shares during the period. Finally, Rafferty Asset Management LLC increased its stake in shares of Accuray by 47.0% in the 2nd quarter. Rafferty Asset Management LLC now owns 26,905 shares of the medical equipment provider’s stock valued at $53,000 after buying an additional 8,597 shares during the period. Institutional investors own 63.42% of the company’s stock.

Accuray Stock Down 1.0 %

NASDAQ ARAY opened at $2.90 on Wednesday. The stock has a fifty day moving average of $2.51 and a 200-day moving average of $2.31. The stock has a market capitalization of $276.95 million, a P/E ratio of -22.31 and a beta of 1.54. Accuray Incorporated has a 52 week low of $1.70 and a 52 week high of $3.67. The company has a debt-to-equity ratio of 3.36, a quick ratio of 0.98 and a current ratio of 1.82.

Accuray (NASDAQ:ARAY – Get Rating) last released its earnings results on Wednesday, February 1st. The medical equipment provider reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. Accuray had a negative return on equity of 23.23% and a negative net margin of 2.83%. The company had revenue of $114.76 million during the quarter, compared to analysts’ expectations of $106.28 million. On average, equities research analysts forecast that Accuray Incorporated will post -0.05 EPS for the current year.

Accuray Company Profile

(Get Rating)

Accuray, Inc is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy.